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Abstract 
We present clinical, neuropathy and corneal nerve morphology data in a participant 
with type 2 diabetes who developed diabetic foot ulceration, partial amputation and 
Charcot during a longitudinal observational study. While conventional measures of 
neuropathy did not deteriorate significantly, corneal nerve parameters showed a 
rapid reduction prior to the development of foot complications. 
Keywords: Diabetic peripheral neuropathy; corneal nerve morphology; diabetic foot 
complications 
   
1. Introduction 
Diabetic peripheral neuropathy (DPN), a common and chronic complication of 
diabetes, can lead to foot ulceration, Charcot foot and amputation with a significant 
impact on the quality of life of the patient and markedly increased health care costs 
[1,2]. These end points have been attributed primarily to a loss of protective 
sensation and large fibre neuropathy [3]. 
In vivo corneal confocal microscopy (IVCCM) [4] emerged more than a decade ago 
as a measure of small fibre neuropathy for DPN assessment [5] and has 
demonstrated considerable utility in early diagnosis [6], stratification of severity [7]  
and assessment of therapeutic efficacy [8,9] in DPN. This case report demonstrates 
that IVCCM identifies and tracks a rapid decline in small nerve fibres in relation to 
the development of diabetic foot ulceration and Charcot. 
2. Case report 
Data were collected prospectively over 7 years commencing from June 2009 from a 
55 year old Caucasian male with type 2 diabetes (diagnosed in 2002) who was a 
participant in the LANDMark study [9]. The participant underwent examinations at 
baseline and at four subsequent visits and a final visit approximately 6.5 years from 
baseline. Annual assessments comprised of HbA1c, lipid profile and blood pressure 
and detailed evaluation of peripheral neuropathy including neuropathy disability 
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score (NDS), quantitative sensory testing (QST) of thermal and vibration perception, 
nerve conduction studies (NCS) and corneal nerve parameters measured using 
IVCCM. At baseline, no biochemistry and NCS were conducted for this participant, 
because these were not a part of the study protocol in 2009. Furthermore, no 
neuropathy assessment could be carried out (except IVCCM) at year-3 and final 
visits because of DPN complications of the affected right foot. 
The following blood biochemistry parameters were recorded at year-1, year-2, year-
3, year-4 and final year-6.5 visits: HbA1c – 7.5, 8.7, 9.3, 8.0 and 9.8 % (58, 72, 78, 
64 and 84 mmol/mol); total cholesterol: 4.0, 5.1, 4.8, 3.0 and 5.2 mmol/L; HDL-
cholesterol: 0.6, 0.9, 0.7, 0.7 and 0.7 mmol/L; LDL-cholesterol: 1.8, 2.9, 2.5. 1.0 and 
3.3 mmol/L; Triglycerides: 3.4, 2.9, 3.4, 2.8 and 2.6 mmol/L (Figure 1a). Blood 
pressure was measured from baseline to final visit as follows:  systolic: 123, 127, 
109, 140, 119 and 115 mmHg; diastolic: 81, 80, 69, 82, 95 and 77 mmHg. The 
following neuropathy measures were recorded at baseline, year-1, year-2 and year-4 
visits: NDS: 9, 10, 6 and 8; cold detection threshold: 20, 30, 28 and 30 °C; warm 
detection thresholds: 40, 34, 37 and 35 °C; vibration perception threshold: 8, 4, 6 
and 7 Hz. In relation to NCS, no reproducible responses were elicited for the sural 
sensory nerve at any of the visits. Peroneal motor nerve conduction velocity 
(PMNCV, ankle to fibula head) was 34, 38 and 34 m/s for year-1, year-2 and year-4 
visits. Figure 1b illustrates the trends over time in conventional measures of 
neuropathy. 
The participant developed an ulcer on his right great toe 2.7 years after his baseline 
visit which healed after six months. In November 2012 (3.4 years after baseline) he 
underwent partial left great toe amputation secondary to a foot ulcer initiated 5 
months prior to the amputation. The participant developed Charcot’s foot (midfoot 
collapse) in November 2015 (approximately 6.5 years from baseline) and underwent 
IVCCM examination. IVCCM demonstrated a moderate to severe neuropathy at 
baseline followed by a rapid decline in corneal nerve fibre density (CNFD), nerve 
branch density (CNBD) and fibre length (CNFL) over the duration of the study 
(Figure 1c).  
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3. Discussion 
Patients with diabetes may develop a spectrum of end stage complications as a 
consequence of DPN. There is a need for reliable methods to accurately discriminate 
those patients at higher risk of foot complications from those who are not. An 
abnormality in neurological examination, monofilament insensitivity and loss of 
vibration perception are traditionally deployed to identify patients at high risk of foot 
ulceration, whilst neurophysiology is advocated as the gold standard for identifying 
patients with DPN [3]. Alternative techniques such as IENFD and IVCCM 
assessment can also diagnose diabetic neuropathy [11] and help stratify the stage of 
neuropathy [7]. In relation to the case reported here we have compared the utility of 
a range of advocated measures of neuropathy, including IVCCM in relation to the 
development of both foot ulceration and Charcot foot. 
Although with some notable variations, during the 6.5 years of observation the 
participant had poor glycaemic control and non-optimal lipid management evident by 
above optimal levels of LDL-cholesterol and triglycerides and suboptimal levels of 
HDL-cholesterol; however, the blood pressure control was acceptable. NDS showed 
variability but overall the patient had moderate to severe neuropathy. Thermal and 
vibration perception and PMNCV improved from baseline to the year-1 visit, but 
these measures at all remaining visits showed no deterioration, especially in relation 
to the occurrence of foot ulceration, amputation or the development of Charcot foot.  
Notably, all corneal nerve parameters showed a reduction prior to the development 
of foot ulceration and partial amputation and also continued to decline before the 
development of Charcot’s foot at the final visit. Over the 6.5 years of follow up, 
CNFD, CNBD and CNFL showed an annual rate of deterioration of 1.9 nerve/mm2, 
2.8 branch/mm2 and 1.1 mm/mm2, respectively. This reduction is much more marked 
than that observed in healthy control subjects in whom we have previously shown a 
linear decrease of 0.05 mm/mm2 in CNFL per one year increase in age [12,13]  and 
a reduction of 1 nerve/mm2 (CNFD) per year with no change in CNBD and CNFL in 
individuals with type 1 diabetes [14].     
Sensory small nerve fibres play an important role in the process of wound healing in 
diabetes [15]. This case report implies a potential value of IVCCM as compared to 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
QST and neurophysiology in identifying a dramatic loss of small nerve fibres and 
consequently predicting the future development of foot ulceration and Charcot. This 
technique may allow the identification of high risk individuals who may benefit from 
diabetic foot care programs and educational interventions, or who may enter clinical 
trials of interventions for the prevention of the development of the late sequelae of 
neuropathy. Future research should focus on the levels of longitudinal corneal nerve 
change that can discriminate those who are at risk of foot complications. 
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Figure Legends 
Figure 1. Changes in (a) blood biochemistry parameters, (b) conventional measures 
of neuropathy and (c) corneal nerve parameters in this case over 6.5 years of follow-
up and occurrence of foot complications. NDS: neuropathy disability score; CDT: 
cold detection threshold; WDT: warm detection threshold; VPT: vibration perception 
threshold; PMNCV: peroneal motor nerve conduction velocity; CNFD: corneal nerve 
fibre density; CNBD: corneal nerve branch density and CNFL: corneal nerve fibre 
length.  
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Figure 1 
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